Full metadata record
DC FieldValueLanguage
dc.creatorDeza, S. (Sara)-
dc.creatorMaroto-García, J. (Julia)-
dc.creatorTellechea, O. (Olaia)-
dc.creatorOrbegozo, N. (Natalia)-
dc.creatorMerino, J. (Juana)-
dc.creatorGalofre, J.C. (Juan Carlos)-
dc.creatorAlegre-Martinez, E. (Estibaliz)-
dc.creatorGonzalez-Hernandez, A. (Alvaro)-
dc.date.accessioned2023-09-20T08:25:47Z-
dc.date.available2023-09-20T08:25:47Z-
dc.date.issued2023-
dc.identifier.citationDeza-Casquero, S. (Sara); Maroto-García, J. (Julia); Tellechea, O.; et al. "Clinical implications of changing thyroglobulin and antithyroglobulin antibodies analytical methods in the follow-up of patients with differentiated thyroid carcinoma". Clinica Chimica Acta. 548, 2023, 117502es
dc.identifier.issn0009-8981-
dc.identifier.urihttps://hdl.handle.net/10171/67252-
dc.description.abstractBackground and aims: Patients' response to treatment in differentiated thyroid cancer (DTC) is classified according to serum thyroglobulin concentrations (Tg), usually using the American Thyroid Association guidelines and considering potential interfering anti-thyroglobulin antibodies (Ab-Tg). We aim to evaluate the clinical implications of changing Tg and Ab-Tg quantification method. Material and methods: Tg and Ab-Tg were quantified in 82 serum samples (60 from DTC patients) by Elecsys and Access immunoassays. Results: Elecsys immunoassay rendered higher values of Tg than Access: mean bias 5.03 ng/mL (95%CI:-14.14-24.21). In DTC patients, there was an almost perfect agreement for response classification (kappa index=0.833). Discrepancies appeared in patients with undetermined response, with a more tendency to subclassification with Access. Ab-Tg showed a poor correlation (r=0.5394). When Elecsys cut-off was reduced to 43 IU/mL, agreement for positive/negative classification improved from a kappa index of 0.607 to 0.650. Prospective study with personalized follow-up showed that only 6.3% of Tg results required an analytical confirmation, being confirmed 93% of them. Conclusions: Despite the biases observed, clinical impact of an analytical change is minimal in patients' management. However, cautious and personalized follow-up period after the change is still mandatory, especially in patients with Tg levels between 0.2 and 1 ng/mL.-
dc.language.isoen-
dc.rightsinfo:eu-repo/semantics/openAccess-
dc.subjectAssay-
dc.subjectThyroglobulin-
dc.subjectDifferentiated thyroid cancer-
dc.subjectAnti-thyroglobulin antibodies-
dc.subjectMethod comparison-
dc.subjectImmunoassay-
dc.subjectAutoantibody-
dc.subjectCancer-
dc.titleClinical implications of changing thyroglobulin and antithyroglobulin antibodies analytical methods in the follow-up of patients with differentiated thyroid carcinoma-
dc.typeinfo:eu-repo/semantics/article-
articulos.autor.creadorManagment-
articulos.autor.creadorPerformance-
dc.description.noteThis is an open access article under the CC BY-NC license-
dc.identifier.doi10.1016/j.cca.2023.117502-
dadun.citation.publicationNameClinica Chimica Acta-
dadun.citation.startingPage117502-
dadun.citation.volume548-
dc.identifier.pmid37516333-

Files in This Item:
Thumbnail
File
pdf.pdf
Description
Size
615.88 kB
Format
Adobe PDF


Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.